Market Research Life Sciences Market Research Biotechnology Market Research Cell Culture Market Research

Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report, By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements), By End Use, By Region, And Segment Forecasts, 2024 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 120 Pages Grand View Research January, 2024 GV18531870
Best Price Guarantee
Price from $5,950
Length 120 Pages
Publisher Grand View Research
Published Date January, 2024
SKU GV18531870

Cell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report, By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements), By End Use, By Region, And Segment Forecasts, 2024 - 2030


Cell Therapy Human Raw Materials Market Growth & Trends

The global cell therapy human raw materials market size is expected to reach USD 11.44 billion by 2030 and is projected to expand at a CAGR of 22.32% from 2024 to 2030 according to a new report by Grand View Research, Inc. This is attributed to increasing investment in cell therapy research & development, growing number of clinical trials and rising adoption of regenerative & personalized medicines.

The field of cell therapy R&D has seen substantial growth in investments in recent years, fueling the development of next-generation treatments like CAR T-cell therapies. This surge in activity has advanced the understanding of cell biology, immunology, & gene editing, leading to the identification of novel therapeutic targets and the optimization of cell manufacturing processes. The improved understanding of the tumor microenvironment and immune system evasion mechanisms has enabled researchers to design CAR-T cells that effectively target and eliminate cancer cells. These advancements are being driven by increased funding in cancer immunotherapy research and are expected to propel the cell therapy raw materials market. For instance, in August 2023, Cellares, a startup specializing in cell therapy production, secured an additional USD 255 million in funding as investors continued to invest heavily in the company. Bristol Myers Squibb is among the supporters of Cellares, which asserts that its manufacturing

apabilities can outperform traditional Contract Development and Manufacturing Organization (CDMO) facilities.

Furthermore, the expanding landscape of clinical trials in the field of cell therapy has become a driving force influencing the cell therapy human raw materials market. As the number of clinical trials investigating the efficacy and safety of cell-based therapies continues to rise, the demand for specific raw materials essential to these trials is experiencing a considerable upswing.

However, ethical concerns in stem cell research restrain the cell therapy human raw materials market, shaping the landscape with unique challenges. One prominent ethical dilemma revolves around the use of human-derived materials, particularly stem cells, which raises issues regarding the source, consent, and potential exploitation. Obtaining these materials may involve ethical considerations related to embryonic stem cells, as their extraction typically involves the destruction of embryos, sparking debates on the moral status of the early human life involved.

Cell Therapy Human Raw Materials Market Report Highlights
  • The cell culture supplements segment dominated the product segment with a revenue share of 27.84% in 2023, owing to the rising demand for animal-free cell-based therapies
  • The cell culture media segment is expected to grow at the fastest CAGR over the forecast period due to the advancements in cell culture media technology which focuses on development of specialized formulations
  • Based on end use, the biopharmaceutical & pharmaceutical companies segment dominated the market in 2023. On the other hand, the CROs & CMOs segment is expected to witness the fastest growth over the forecast period
  • North America region dominated the market owing to factors such as the presence of key market players like Thermo Fisher Scientific, Inc, Actylis, ACROBiosystems and the growth in pharmaceutical & biotechnology research sectors in this region
  • Asia Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in regions like Japan
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Product
1.1.2. End Use
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. Increasing investments in cell therapy research and development
3.2.1.2. Growing number of clinical trials
3.2.1.3. Rising adoption of regenerative medicine
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. Ethical concerns related to stem cell research
3.2.2.2. High cost associated with the production and procurement of raw materials
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Cell Therapy Human Raw Materials Market: Product Movement Analysis
4.2. Cell Culture Media
4.2.1. Cell culture media market estimates and forecasts, 2018 - 2030 (USD Million)
4.3. Cell Culture Sera
4.3.1. Cell culture sera market estimates and forecasts, 2018 - 2030 (USD Million)
4.4. Cell Culture Supplements
4.4.1. Cell culture supplements market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.2. Proteins
4.4.2.1. Proteins market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.3. Growth Factors
4.4.3.1. Growth factors market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.4. Nucleotides
4.4.4.1. Nucleotides market estimates and forecasts, 2018 - 2030 (USD Million)
4.4.5. Other Supplements
4.4.5.1. Other supplements market estimates and forecasts, 2018 - 2030 (USD Million)
4.5. Reagents & Buffers
4.5.1. Reagents & buffers market estimates and forecasts, 2018 - 2030 (USD Million)
4.6. Other Raw Materials
4.6.1. Other raw materials market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. End Use Group Business Analysis
5.1. Cell Therapy Human Raw Materials Market: End Use Movement Analysis
5.2. Biopharmaceutical & Pharmaceutical Companies
5.2.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
5.3. CROs & CMOs
5.3.1. CROS & CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
5.4. Academic & Research Institutions
5.4.1. Academic & research institutions market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Cell Therapy Human Raw Materials Share By Region, 2023 & 2030
6.2. North America
6.2.1. North America Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Competitive Scenario
6.2.2.3. Regulatory Framework
6.2.2.4. Target Disease Prevalence
6.2.2.5. U.S. Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Competitive Scenario
6.2.3.3. Regulatory Framework
6.2.3.4. Target Disease Prevalence
6.2.3.5. Canada Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. Target Disease Prevalence
6.3.2.5. UK Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Target Disease Prevalence
6.3.3.5. Germany Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Target Disease Prevalence
6.3.4.5. France Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Competitive Scenario
6.3.5.3. Regulatory Framework
6.3.5.4. Target Disease Prevalence
6.3.5.5. Italy Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Competitive Scenario
6.3.6.3. Regulatory Framework
6.3.6.4. Target Disease Prevalence
6.3.6.5. Spain Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Competitive Scenario
6.3.7.3. Regulatory Framework
6.3.7.4. Target Disease Prevalence
6.3.7.5. Denmark Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Competitive Scenario
6.3.8.3. Regulatory Framework
6.3.8.4. Target Disease Prevalence
6.3.8.5. Sweden Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Competitive Scenario
6.3.9.3. Regulatory Framework
6.3.9.4. Target Disease Prevalence
6.3.9.5. Norway Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. Target Disease Prevalence
6.4.2.5. Japan Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Target Disease Prevalence
6.4.3.5. China Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Target Disease Prevalence
6.4.4.5. India Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Target Disease Prevalence
6.4.5.5. Australia Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Target Disease Prevalence
6.4.6.5. Thailand Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Target Disease Prevalence
6.4.7.5. South Korea Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Target Disease Prevalence
6.5.2.5. Brazil Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Target Disease Prevalence
6.5.3.5. Mexico Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.5.4. Argentina
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. Target Disease Prevalence
6.5.4.5. Argentina Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Target Disease Prevalence
6.6.2.5. South Africa Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Target Disease Prevalence
6.6.3.5. Saudi Arabia Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Target Disease Prevalence
6.6.4.5. UAE Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Target Disease Prevalence
6.6.5.5. Kuwait Cell Therapy Human Raw Materials, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. Thermo Fisher Scientific, Inc
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Merck KGaA
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Actylis
7.4.3.1. Overview
7.4.3.2. Product Benchmarking
7.4.3.3. Strategic Initiatives
7.4.4. ACROBiosystems
7.4.4.1. Overview
7.4.4.2. Product Benchmarking
7.4.4.3. Strategic Initiatives
7.4.5. STEMCELL Technologies
7.4.5.1. Overview
7.4.5.2. Product Benchmarking
7.4.5.3. Strategic Initiatives
7.4.6. Grifols, S.A.
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Charles River Laboratories
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. RoosterBio, Inc.
7.4.8.1. Overview
7.4.8.2. Product Benchmarking
7.4.8.3. Strategic Initiatives
7.4.9. PromoCell GmbH
7.4.9.1. Overview
7.4.9.2. Product Benchmarking
7.4.9.3. Strategic Initiatives
7.4.10. Danaher
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. BioIVT
7.4.11.1. Overview
7.4.11.2. Product Benchmarking
7.4.11.3. Strategic Initiatives
7.4.12. GeminiBio
7.4.12.1. Overview
7.4.12.2. Product Benchmarking
7.4.12.3. Strategic Initiatives
7.4.13. Akron Biotech
7.4.13.1. Overview
7.4.13.2. Product Benchmarking
7.4.13.3. Strategic Initiatives
7.4.14. AllCells
7.4.14.1. Overview
7.4.14.2. Product Benchmarking
7.4.14.3. Strategic Initiatives
7.4.15. CGT Global
7.4.15.1. Overview
7.4.15.2. Product Benchmarking
7.4.15.3. Strategic Initiatives

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings